Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR949929Aexternal-prioritypatent/FR1468636A/fr
Application filed by Roussel Uclaf SAfiledCriticalRoussel Uclaf SA
Priority to FR959561ApriorityCriticalpatent/FR3317M/fr
Application grantedgrantedCritical
Publication of FR3317MpublicationCriticalpatent/FR3317M/fr
C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J75/00—Processes for the preparation of steroids in general
Landscapes
Chemical & Material Sciences
(AREA)
Organic Chemistry
(AREA)
Health & Medical Sciences
(AREA)
General Health & Medical Sciences
(AREA)
FR959561A1963-10-081964-01-07Nouveau médicament notamment pour le traitement des troubles dus a une insuffisance du corps jaune.
ExpiredFR3317M
(fr)
Nouveau médicament notamment pour le traitement des manifestations de l'hyperémotivé, de l'anxiete et des troubles dus a l'hyperexcitabilité.
Nouveau médicament notamment pour le traitement des manifestations de l'hyperémotivite, de l'anxiété et des troubles dus a l'hyperexcitabilité.